Financial Performance - The estimated net profit attributable to shareholders for 2022 is projected to be between 11,000 and 12,500 thousand yuan, representing an increase of 41.22% to 60.48% compared to the previous year's net profit of 7,789.07 thousand yuan [3]. - The growth in net profit is primarily driven by the steady increase in sales volume of existing products and the launch of new products such as Ipatasertib tablets and Acarbose tablets, which have contributed to sustainable growth in operating performance [5]. - Significant sales growth was observed in the promoted compound products "Furuitong" and "Bokaiqing," leading to an increase in the number of patients served and an optimization of the product structure, enhancing the overall gross profit margin [5]. Management and Operations - The company has strengthened internal management, optimized personnel structure, and strictly controlled expenses, resulting in improved profitability [5]. - The financial data presented is preliminary and has not been audited, and the final figures will be disclosed in the official 2022 annual report [6].
德源药业(832735) - 2022 Q4 - 年度业绩预告